2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkers
2017
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER- cancersER cohortNeoadjuvant pertuzumabWeekly paclitaxel
2012
DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer M, Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. DOI: 10.1200/jco.2012.30.15_suppl.1012.Peer-Reviewed Original ResearchPathological complete responseHigher pathological complete responseBreast cancer molecular subtypesTaxane-based regimensTaxane-containing regimensCisplatin-containing regimensMolecular breast cancer subtypesTaxane-based chemotherapyPotential predictive markerBreast cancer subtypesCancer molecular subtypesBC cell linesFalse discovery correctionDistant relapseComplete responseBetter prognosisPoor prognosisPredictive factorsPrognostic valueBC subtypesER-/HER2Predictive markerN patientsPrognostic markerMolecular subtypes
2008
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer. Breast Cancer Research 2008, 10: r27. PMID: 18371219, PMCID: PMC2397526, DOI: 10.1186/bcr1984.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClass I Phosphatidylinositol 3-KinasesDNA Mutational AnalysisFemaleHumansLymphatic MetastasisMiddle AgedMutationNeoadjuvant TherapyNeoplasm StagingPhosphatidylinositol 3-KinasesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTaxoidsConceptsPathological complete responseER-positive tumorsPIK3CA mutationsBreast cancerChemotherapy sensitivityPIK3CA exon 9 mutationsStage IIResidual cancer burden scoreER-negative breast tumorsReceptor expression statusNode-positive diseaseResultsTwenty-three patientsTaxane-based chemotherapyType of chemotherapyNode-positive tumorsPIK3CA-activating mutationsEstrogen receptor (ER) expression statusExon 9 mutationsPIK3CA activationRCB scoreChemotherapy regimenNeoadjuvant chemotherapyComplete responseResidual cancerER status